Hospital guidelines for use of low-molecular-weight heparins

Annals of Pharmacotherapy

Volumn 37, Issue 7-8, 2003, Pages 1072-1081

  Nutescu, Edith A ^a   Lewis, Richard K ^a,b   Finley, Jamie M ^a   Schumock, Glen T ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Mercy Resource Management Inc   (United States)

^c M/C 886 ^*  (United States)

Author keywords

Anticoagulation; Low molecular weight heparins; Prescribing guidelines

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; EPIDURAL ANESTHESIA; HEALTH CARE SYSTEM; HEART MUSCLE ISCHEMIA; HOSPITAL; HUMAN; LUNG EMBOLISM; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

EID: 0038441787     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C400     Document Type: Review

References (73)

1. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991;266:2847-51.
2. Swanson CN, Keys PW. Evaluation of an indirect method of detecting adverse reactions to anticoagulants. Am J Hosp Pharm 1987;44:544-8.
3. Savitsky ME. Recognizing hospital adverse drug reactions. J Pharm Pract 1989;2:203-8.
4. Armstrong EP. Evaluating low-molecular-weight heparins within a health system: issues and strategies. Formulary 1999;34:144-8.
5. Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS. Economic analysis of low-dose heparin vs. the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med 1999;159:1221-8.
6. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness study. Ann Intern Med 1999;130:789-99.
7. Schumock GT, Nutescu EA, Walton SW, Arondekar BV, Lewis RK. Survey of hospital policies regarding low-molecular-weight heparins. Am J Health Syst Pharm 2002;59:534-8.
8. Bollinger KA, Vermeulen LC, Davis SN, Geurkink EA. Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange. Am J Health Syst Pharm 2000;57:368-72.
9. Bollinger KA, Vermeulen LC, Davis SN, Geurkink EA. Therapeutic interchange of low-molecular-weight heparins (letter). Am J Health Syst Pharm 2000;57:1801-2.
10. Burnakis TG. Therapeutic interchange of low-molecular-weight heparins (letter). Am J Health Syst Pharm 2000;57:1797-8.
11. Bussey HI, Hawkins DW, Groce JB. Therapeutic interchange of low-molecular-weight heparins (letter). Am J Health Syst Pharm 2000;57:1800-1.
12. Gonzalez LG. Therapeutic interchange of low-molecular-weight heparins (letter). Am J Health Syst Pharm 2000;57:1798-800.
13. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. Can Med Assoc J 1997;156:1705-12.
14. Chrischilles EA, Gondek K. Do practice guidelines augment drug utilization review? Pharmacoeconomics 1997;12:648-66.
15. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39(suppl 8):II46-54.
16. American Society of Health-System Pharmacists. ASHP statement on the Pharmacy and Therapeutics Committee. Am J Hosp Pharm 1992;49:2008-9.
17. Vermeulen LC, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus: the University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med 1995;155:373-9.
18. Ratko TA, Burnett DA, Garrett E, Matuszewski K, Sacher RA, The University Hospital Consortium Expert Panel on Off-label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;27:1865-70.
19. Dalen JA, Hirsh J, eds. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001;119(suppl):1S-370S.
20. ACCP/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. Catheter Cardiovasc Interv 2000;51:505-21.
21. ACOG Committee Opinion. Anticoagulation with low-molecular-weight heparin during pregnancy. No. 211, November 1998. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 1999;65:89-90.
22. Laposata M, Green D, Van Cott EM, Barowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799-807.
23. Brook RH, Chassin MR, Fink A, Solomon DH, Kosekoff J, Park RE. A method for detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986;2:53-63.
24. Campbell SM, Cantrill JA. Consensus methods in prescribing research. J Clin Pharm Ther 2001;26:5-14.
25. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, et al. Prevention of venous thromboembolism. Chest 2001;119(1 suppl):132S-75S.
26. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(1 suppl):176S-93S.
27. Cairns JA, Theroux P, Lewis D, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest 2001;119(1 suppl):228S-52S.
28. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
29. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (T1MI) 11B trial. Circulation 1999;100:1593-601.
30. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-8.
31. Horlocker TT, Wendel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998;23(6 suppl 2):164-77.
32. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-65.
33. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501.
34. Nurmohamed MT, Verhaeghe R, Haas S, Triarte JA, Vogel G, Van Rij AM, et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995;169:567-71.
35. Enoxacan study group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099-103.
36. Taberner DA, Poller L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. BMJ 1978;1:272-4.
37. Francis CW, Pellegrini VD, Totterman S, Boyd AD Jr, Marder VJ, Liebert KM, et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997;79:1365-72.
38. Pineo GF, Hull RD. A double-blind randomized comparison of low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery (abstract). Blood 1999;94:30a.
39. Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40.
40. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35.
41. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Basier RB, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group. Ann Intern Med 1994;121:81-9.
42. Hull R, Raskob G, Pineo G. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
43. Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle J, et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;80:22-5.
44. Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs. postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999;159:137-41.
45. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Esperance B, Demers C, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-26.
46. Spiro TE, Fitzgerald W, Trowbridge AA. Enoxaparin, a low molecular weight heparin, and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery (abstract). Blood 1994;84:246a.
47. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med 1998;158:873-8.
48. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, et al. Prevention of deep vein thrombosis in elderly medical patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986;16:159-64.
49. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of VTE in acutely ill medical patients. N Engl J Med 1999;341:793-800.
50. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against VTE after major trauma. N Engl J Med 1996;335:701-7.
51. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of VTE after elective neurosurgery. N Engl J Med 1998;339:80-5.
52. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998;43:1074-81.
53. Green D, Lee MY, Lim AC, Chmiel JS, Vetter M, Pang T, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990;113:571-4.
54. Dolovich LP, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-8.
55. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
56. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
57. Spiro TE. A multicenter clinical trial comparing once and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thromb Haemost 1997;77(suppl):373-4.
58. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
59. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-9.
60. Luomanmaki K, Granqvist S, Hallert C, Jauro I, Ketla K, Kim HC, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med 1996;240:85-92.
61. Partsch H, Kechavarz B, Mostbeck A, Kohn H, Lipp C. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low -molecular-weight heparin. J Vasc Surg 1996;24:774-82.
62. Meyer G, Brenot F, Pacouret G, Simmoneau G, Gillet Juvin K, Charbonnier B, et al. Subcutaneous low-molecular-weight heparin (Fragmin) versus unfractionated heparin in the treatment of acute non-massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-5.
63. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
64. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
65. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-36.
66. Davidson BL. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis. Sem Thromb Hemost 1999;25(suppl 3):107-12.
67. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
68. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-3.
69. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158:1809-12.
70. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
71. Crowther M, Hirsh J. Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Sem Thromb Hemost 1997;23:77-81.
72. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:701-7.
73. Turpie AG. Can we differentiate the low molecular weight heparins? Clin Cardiol 2000;23:14-7.